Clinical trials: Cardiovascular Disease (CKD)
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, Bloodpressure
Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD
The transition from chronic kidney disease (CKD) to end-stage renal disease ESRD is a vulnerable and challenging period of time for patients and providers.
- Conditions
- Chronic Kidney Disease, Bloodpressure, Hypertension
- Trial name
- PERFORMANCE (NCT02975505)
- Testing
- Strict blood pressure control
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of California, San Francisco
Hypertension, Chronic Kidney Diseases
Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease
The purpose of this study to test whether n-of-1 trial-guided clinical decision-making improves blood pressure control in hypertensive children with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
- Trial name
- NCT04591171
- Testing
- n-of-1 trial guided clinical decision making
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Health Science Center, Houston
Hypertension, Chronic Kidney Disease
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.
- Trial name
- NCT01365481
- Testing
- Valsartan, amlodipine, Hydrochlorothiazide
- Where
- 28 sites in Colombia, Finland and 8 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension
The purpose of this extension study is to compare the long-term safety of valsartan versus enalapril, and the effectiveness of the combination of valsartan and enalapril versus enalapril alone in children with hypertension.
- Trial name
- NCT00446511
- Testing
- Valsartan, Enalapril
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Cardiovascular Risk Factor
Activity Trackers for Improving BP
The study aims to determine if use of physical activity trackers coupled with provider feedback will increase awareness of young adults of their physical fitness and improve blood pressure levels.
- Conditions
- Hypertension, Cardiovascular Risk Factor, Physical Activity, Chronic Kidney Diseases
- Trial name
- NCT03325426
- Testing
- FitBit
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of California, San Francisco
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
This study is conducted in Europe. The aim of this study is to compare the easiness of use of Norditropin NordiFlex® device to the device previously used by patients or parents.
- Conditions
- Growth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem, Small for Gestational Age
- Trial name
- NCT01245374
- Testing
- Norditropin NordiFlex®
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Novo Nordisk A/S